Turmeric vs Boswellia for Perimenopause Inflammation and Joint Pain
Turmeric and boswellia both target inflammation through different pathways. Compare their evidence, bioavailability, dosing, and safety for perimenopause.
Inflammation and Perimenopause: Why It Matters
Joint pain, stiffness, and generalised aching are among the most underappreciated symptoms of perimenopause. Oestrogen has significant anti-inflammatory properties, and as levels decline, many women notice increased inflammation throughout the body. This can worsen existing conditions and create new discomfort in joints that were previously untroubled. Both turmeric (specifically its active compound curcumin) and boswellia (Boswellia serrata, also called Indian frankincense) are among the most researched plant-derived anti-inflammatory compounds, and they work through different biological pathways. Comparing them carefully helps you choose the right tool for your symptoms.
How Turmeric and Curcumin Work
Curcumin, the polyphenol responsible for turmeric's yellow colour and most of its studied effects, suppresses inflammation primarily through inhibition of the transcription factor NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells). NF-kB regulates the expression of a wide range of pro-inflammatory genes, including those that produce cytokines like TNF-alpha and interleukin-6. By blocking NF-kB activation, curcumin reduces the production of these signalling molecules across multiple tissue types. It also inhibits COX-2 enzymes, similar to ibuprofen, and has antioxidant effects that reduce oxidative stress. Human trials have shown benefits for osteoarthritis, rheumatoid arthritis, metabolic syndrome, and exercise-induced muscle soreness.
How Boswellia Works
Boswellia resin contains boswellic acids, particularly AKBA (acetyl-11-keto-beta-boswellic acid), which inhibit the 5-LOX (5-lipoxygenase) enzyme. This is a different inflammatory pathway from NF-kB. The 5-LOX pathway produces leukotrienes, inflammatory mediators that play a significant role in joint inflammation and are particularly relevant in osteoarthritis and inflammatory joint conditions. Boswellia also appears to inhibit the breakdown of cartilage and may have a relatively rapid onset of action compared to some other anti-inflammatory supplements. Clinical trials have shown reductions in knee pain, stiffness, and improved physical function in people with osteoarthritis, with effects sometimes noted within two to four weeks.
Bioavailability: The Critical Issue for Curcumin
Curcumin has notoriously poor bioavailability when taken as plain turmeric powder or a standard extract. It is rapidly metabolised and poorly absorbed from the gut. Black pepper extract (piperine) at around 20 mg per dose increases curcumin absorption by approximately 2,000 percent by inhibiting gut-wall and liver metabolism. Many good-quality turmeric supplements include piperine for this reason. There are also patented curcumin formulations designed to improve absorption through lipid complexes, nanoparticles, and phospholipid delivery systems. Look for products that specify their bioavailability enhancement method rather than simply listing a high curcumin percentage. Boswellia is generally better absorbed, though quality and standardisation of boswellic acid content still varies widely between products.
Dosing and Safety Profiles
Curcumin supplements typically range from 500 mg to 1,500 mg of curcumin per day in human trials showing effects, often divided into two or three doses. At these levels, side effects are uncommon. High doses may cause nausea or loose stools in some people. Boswellia is commonly studied at doses of 100 to 500 mg of standardised extract per day. It is well tolerated, with occasional GI discomfort reported. Both are generally considered safe for short to medium-term use. Long-term safety data beyond six months is more limited for boswellia, though it has been used traditionally for centuries without documented toxicity. Neither compound has the gastric or cardiovascular risks associated with long-term NSAID use.
Drug Interactions to Consider
Curcumin has mild antiplatelet effects and may interact with anticoagulants such as warfarin, increasing bleeding risk. It can also inhibit certain liver enzymes (CYP3A4, CYP2D6) that metabolise a range of medications, potentially altering their blood levels. People taking tamoxifen, chemotherapy, or multiple prescription drugs should check with their GP or pharmacist before supplementing. Boswellia has fewer documented interactions but should be used with caution in people on non-steroidal anti-inflammatory drugs since the mechanisms partly overlap and the combined effect on inflammation pathways is not well studied. Pregnant women should avoid therapeutic doses of either supplement.
Which One to Choose for Perimenopausal Inflammation
If your primary concern is joint pain and stiffness, particularly in the knees or weight-bearing joints, boswellia has some of the strongest specific joint-pain trial evidence and tends to act relatively quickly. If your concern is broader systemic inflammation, oxidative stress, or you have comorbidities like metabolic syndrome, curcumin's wider mechanism may be preferable. Some women use both together, since they target different inflammatory pathways and are not redundant in combination. There is emerging evidence for synergistic effects. Whichever you choose, quality and standardisation matter more than brand, and tracking your joint pain and symptoms over several weeks in an app like PeriPlan helps you evaluate whether the supplement is making a meaningful difference before committing to long-term use.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.